See also this year's filing and all EDGAR filings for this company.
PDF Report 0001600132_2017_Bellerophon_Therapeutics_Inc.pdf
Logs
| warning | Missing logo | subcommand.report | {} |
| info | NetIncome node detected by tax heuristic | input.sec.calculation_linkbase.edgar_model_mapping | {'net_inc_node': 'NetIncomeLossAvailableToCommonStockholdersBasic'} |
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Liabilities', 'missing_ratio': 0.053057553956834536, 'aggregate_val': 11710000, 'exp_sum': 11120000, 'exp_to_value': {'LiabilitiesCurrent': 6495000, 'LiabilitiesNoncurrent': 0, 'remainder_Liabilities': 4625000}} |
| info | Failed to set obs_EconomicCapitalRatio | industry.us_generic | {'reason': "KeyError('0001600132')"} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001600132, Bellerophon Therapeutics Inc.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 26,505,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 1,399,000 |
| 3 | remainder_Assets | 1,798,000 |
| 4 | LiabilitiesCurrent | 6,495,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 5,215,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 7,107,000 |
| 9 | ResearchAndDevelopmentExpense | 16,650,000 |
| 10 | remainder_Expenses | 152,000 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 95,000 |
| 13 | remainder_ComprehensiveNetIncome | 19,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 29,702,000 |
| 1 | Liabilities | 11,710,000 |
| 2 | Expenses | 23,909,000 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 17,992,000 |
| 5 | NetIncome | -23,814,000 |
| 6 | ComprehensiveNetIncome | -23,804,500 |
| 7 | BaseVar | 32,717,500 |
| 8 | EconomicCapitalRatio | 0.345 |
Edgar->Model Mapping
Feature Distribution
